Suggested remit: To appraise the clinical and cost effectiveness nemolizumab within its marketing authorisation for treating prurigo nodularis in adults
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Further information:
- Status change linked to Topic Selection Decision being set to Selected.
- Process:
- STA Standard
- ID number:
- 6451
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Health Economics Research Unit and Health Services Research Unit, University of Aberdeen
Stakeholders
- Companies sponsors
- Galderma (nemolizumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Allergy UK
- Changing Faces
- Eczema Outreach Support
- Let’s Face It
- National Eczema Society
- Prurigo Nodularis International
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- British Association of Dermatologists
- British Dermatological Nursing Group
- British Geriatrics Society
- British Society for Cutaneous Allergy
- Primary Care Dermatology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- St John’s Institute of Dermatology
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Advanz Pharma (methotrexate)
- Aspen (azathioprine)
- Bristol Myers Squibb (thalidomide)
- Cipla UK (methotrexate)
- Dexcel pharma (ciclosporin)
- Hospira (methotrexate)
- Medac (methotrexate)
- Morningside Healthcare (methotrexate)
- Mylan (azathioprine; ciclosporin)
- Nordic Pharma (methotrexate)
- Nova (azathioprine)
- Novartis Pharmaceuticals (ciclosporin)
- Orion Pharma (methotrexate)
- Rosemont Pharmaceuticals (methotrexate)
- Sandoz (methotrexate)
- Santen UK (ciclosporin)
- Strides Pharma (azathioprine)
- Tillomed Laboratories (azathioprine)
- Zentiva (thalidomide)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- British Skin Foundation
- Centre of Evidence-based Dermatology, University of Nottingham
- Cochrane Skin Group
- Dermatrust
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 April 2025 - 24 April 2025 | Draft guidance |
| 05 March 2025 | Committee meeting: 1 |
| 31 July 2024 | Invitation to participate |
| 18 June 2024 | Please note ID6451 indication is now a separate appraisal from ID6221 indication. The appraisal will be running on the same timelines as ID6221. Please see relevant topic webpages for further information. |
| 09 May 2024 - 07 June 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 09 May 2024 | In progress. Scoping commenced. |
| 18 November 2022 | Awaiting development |
For further information on our processes and methods, please see our CHTE processes and methods manual